echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Differential diagnosis of T1 hyperintensity liver disease

    Differential diagnosis of T1 hyperintensity liver disease

    • Last Update: 2021-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Differential diagnosis : T1 hyperintensity liver disease


    Differential diagnosis : T1 high signal liver disease diagnosis


    Differential Diagnosis: T1 Bright Liver Lesions Differential Diagnosis: T1 Bright Liver Lesions

     

    ① ①

     

    T1 high signal with black ring, T1 high signal with black ring, no enhancement

    T1 high signal with black ring, T1 high signal with black ring, no enhancement
    • T1 bright with a dark rim

    • T2 bright with a dark rim

    • No enhancement

    • No enhancement

  • T1 bright with a dark rim

  • T1 bright with a dark rim

    T1 bright with a dark rim
  • T2 bright with a dark rim

  • T2 bright with a dark rim

    T2 bright with a dark rim
  • No enhancement

  • No enhancement

    No enhancement
  • No enhancement

  • No enhancement

    No enhancement

     

     

     

    Postoperative hematoma 

    Postoperative hematomahematoma 

    Hematoma after surgery

    Hematoma after surgery Hematoma after surgery

     

    ② ②

     

    T1 high signal and low signal focus, T2 low signal and good signal focus, heterogeneous enhancement of the focus, clear solid part

    T1 high signal and low signal focus, T2 low signal and good signal focus, heterogeneous enhancement of the focus, clear solid part
    • T1 very bright within a dark lesion

    • T2 dark with a bright lesion

    • Heterogeneous enhancement within the lesion

    • Washout within the solid lesion

       

  • T1 very bright within a dark lesion

  • T1 very bright within a dark lesion

    T1 very bright within a dark lesion
  • T2 dark with a bright lesion

  • T2 dark with a bright lesion

    T2 dark with a bright lesion
  • Heterogeneous enhancement within the lesion

  • Heterogeneous enhancement within the lesion

    Heterogeneous enhancement within the lesion
  • Washout within the solid lesion

     

  • Washout within the solid lesion

    Washout within the solid lesion

     

     

     

    Carcinoid liver metastases with bleeding

    Carcinoid liver metastases with bleeding Carcinoid liver metastases with bleeding

    Hemorrhagic carcinoid metastasis

    Hemorrhagic carcinoid metastasis Hemorrhagic carcinoid metastasis

     

     

    ③ ③

     

    T1 high signal and low signal focus, T2 mixed signal, irregular ring enhancement, heterogeneous, continuous enhancement

    T1 high signal and low signal focus, T2 mixed signal, irregular ring enhancement, heterogeneous, continuous enhancement
    • T1 bright and dark lesions

    • T2 mixed signal intensity

    • Irregular ring-shaped enhancement

    • Heterogeneous and persistent enhancement

  • T1 bright and dark lesions

  • T1 bright and dark lesions

    T1 bright and dark lesions
  • T2 mixed signal intensity

  • T2 mixed signal intensity

    T2 mixed signal intensity
  • Irregular ring-shaped enhancement

  • Irregular ring-shaped enhancement

    Irregular ring-shaped enhancement
  • Heterogeneous and persistent enhancement

  • Heterogeneous and persistent enhancement

    Heterogeneous and persistent enhancement

     

     

     

    Carcinoid liver metastases and protein production


    Carcinoid liver metastases and protein production


    Protein-producing carcinoid metastasis Protein-producing carcinoid metastasis

     

    ④ ④

     

    T1 is mainly high signal, T2 waits to bright high signal, T1 high signal part is strengthened, heterogeneity continues to strengthen

    T1 is mainly high signal, T2 waits to bright high signal, T1 high signal part is strengthened, heterogeneity continues to strengthen
    • T1 (predominantly) bright lesions

    • T2 isointense to very bright

    • Enhancement of the T1-bright parts

    • Heterogeneous and persistent enhancement

  • T1 (predominantly) bright lesions

  • T1 (predominantly) bright lesions

    T1 (predominantly) bright lesions
  • T2 isointense to very bright

  • T2 isointense to very bright

    T2 isointense to very bright
  • Enhancement of the T1-bright parts

  • Enhancement of the T1-bright parts

    Enhancement of the T1-bright parts
  • Heterogeneous and persistent enhancement

  • Heterogeneous and persistent enhancement

    Heterogeneous and persistent enhancement

     

     

     

    Melanoma liver metastasis

    Melanoma liver metastases Melanoma liver metastases

    Melanoma metastases

    Melanoma metastases Melanoma metastases

     

    summary

    Summary summary
    • Evaluation T1WI: All lesions have high signal components in the non-cirrhotic liver


    • Evaluation on T2WI: In the first case, the lesion was surrounded by a low-signal edge with increased thickness


    • Assessing the enhanced arterial phase: the first case did not have any enhancement, the second case showed uneven enhancement, and the solid part around the lesion was thicker in the third and fourth cases with enhancement


    • Assess the delayed enhancement period: the first case showed no enhancement, the second case was clear with continuous uneven enhancement, and the third and fourth cases continued to have uneven enhancement at the edge of the lesion


  • Evaluation T1WI: All lesions have high signal components in the non-cirrhotic liver


  • Evaluation T1WI: All lesions have high signal components in the non-cirrhotic liver


    Evaluation T1WI: All lesions have high signal components in the non-cirrhotic liver


    Evaluation on T2WI: In the first case, the lesion was surrounded by a low-signal edge with increased thickness


    Evaluation on T2WI: In the first case, the lesion was surrounded by a low-signal edge with increased thickness


    Assessing the enhanced arterial phase: the first case did not have any enhancement, the second case showed uneven enhancement, and the solid part around the lesion was thicker in the third and fourth cases with enhancement


    Assessing the enhanced arterial phase: the first case did not have any enhancement, the second case showed uneven enhancement, and the solid part around the lesion was thicker in the third and fourth cases with enhancement


    Assess the delayed enhancement period: the first case showed no enhancement, the second case was clear with continuous uneven enhancement, and the third and fourth cases continued to have uneven enhancement at the edge of the lesion


    Assess the delayed enhancement period: the first case showed no enhancement, the second case was clear with continuous uneven enhancement, and the third and fourth cases continued to have uneven enhancement at the edge of the lesion
    .

     

     
    • Hematoma: T1 high signal is due to methaemoglobin, and there is a hemosiderin ring at the edge;

    • Hemorrhagic carcinoid metastasis, protein-producing carcinoid metastasis: suggesting metastasis; no specific manifestations; combined with clinical
      .

    • Melanoma metastasis: combined with medical history, T1 high signal; typical arterial phase is obviously enhanced
      .

  • Hematoma: T1 high signal is due to methaemoglobin, and there is a hemosiderin ring at the edge;

  • Hematoma: T1 high signal is due to methaemoglobin, and there is a hemosiderin ring at the edge;

    Hematoma: T1 high signal is due to methaemoglobin, and there is a hemosiderin ring at the edge;
  • Hemorrhagic carcinoid metastasis, protein-producing carcinoid metastasis: suggesting metastasis; no specific manifestations; combined with clinical
    .

  • Hemorrhagic carcinoid metastasis, protein-producing carcinoid metastasis: suggesting metastasis; no specific manifestations; combined with clinical
    .

    Hemorrhagic carcinoid metastasis, protein-producing carcinoid metastasis: suggesting metastasis; no specific manifestations; combined with clinical
    .
  • Melanoma metastasis: combined with medical history, T1 high signal; typical arterial phase is obviously enhanced
    .

  • Melanoma metastasis: combined with medical history, T1 high signal; typical arterial phase is obviously enhanced
    .

    Melanoma metastasis: combined with medical history, T1 high signal; typical arterial phase is obviously enhanced
    .

     

     

    In addition, hepatocellular adenomas are prone to hemorrhage, and can also be manifested as T1 hyperintensity, clear borders, obvious enhancement in the arterial phase, iso-signal in the delayed phase, and surrounding pseudo-capsules
    .
    When combined with massive bleeding, the residual solid part is strengthened
    .

    In addition, hepatocellular adenomas are prone to hemorrhage, and can also be manifested as T1 hyperintensity, clear boundaries, obvious enhancement in the arterial phase, and iso-signal in the delayed phase, and the surrounding pseudocapsules are seen
    .
    When combined with massive bleeding, the residual solid part is strengthened
    .

     

     

     

     

     


     

    ☆  Content source: English book "Liver MRI" ☆  Content source: English book "Liver MRI"

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.